43. The method of claim 41, wherein the human subject is a malignant glioma patient and the method further comprises assessing the risk of tumor progression or tumor metastasis in the patient, presence of glioma stem cells in the sample being indicative of an increased risk for malignant glioma progression or metastasis.

44. The method of any of claims 38-43, wherein the quantifying step is performed by quantitative real-time PCR or in situ hybridization.

45. The use of any one of claims 1-5, 9-14 or 18-24, wherein one or more of the nucleotides in the oligonucleotide are modified by Locked nucleic acids (LNA).